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Abstract 
An experiment to explore renal carcinogenic efficacy of male rat exposure to dietary 
ochratoxin A (OTA) only in the first year of life has been made in comparison to lifetime 
exposure. Ten months exposure to OTA at 300 µg/kg b.w. was sufficient to cause high 
incidence of tumours which became apparent clinically after a latency of up to a year. As a 
putative model for human kidney cancer, the study shows a silent organ-specific 
carcinogenic effect through protracted exposure up to middle age and focused probably on 
very few nephrons. So far, tumourigenesis has not been recognised until in the last quarter 
of natural rat life, but for OTA, rat renal carcinogenesis requires both long exposure and 
only during the first year of normal longevity. The present findings offer an experimental 
framework within which systematic histopathology during tumourigenesis might show 
whether findings of mechanistic studies in key focal neoplasms can reasonably be applied 
to OTA as a putative renal carcinogen for idiopathic kidney cancer in humans. Already, the 
rat tumours mimic those occurring spontaneously in the Eker rat, and there is disparity 
between the large necessary OTA exposure in the rat and the trace amounts of OTA 
consumed by humans. In all such complex considerations it is important to adhere 
rigorously to established principles of disease epidemiology. 
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Introduction 
Ochratoxin A (OTA) is the most potent 
naturally-occurring nephrotoxin causing 
experimental kidney cancer in rats (1), and 
has been recognised as presenting the  
gold standard for log dose/response 
relationships as a thresholded carcinogen 
(2). The comprehensive design of the 
National Toxicology Program (NTP) study 
established that, whereas no renal cancer 
was evident after 9 months of the gavage 
dosing regimen, 15 months of gavage 5 
days/week caused two cases of renal 
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cancer amongst 15 males at the high dose 
(mean daily intake 150 µg/kg b.w.). In a 
larger lifetime study the OTA regimen for 
up to 2 years gave a 60 % incidence of 
renal cancer. Consequently, the NTP study 
has formed the principal experimental 
model for consideration of OTA as a cause 
of human kidney cancer. 
In the context of a major European Union-
funded programme (2001–2004) on OTA’s 
mode of carcinogenicity, opportunity arose 
to develop improved protocols for tumour 
expression and analysis. It was also 
intended to refine understanding of 
experimental optima for tumourigenesis to 
provide a better rat model for debate about 
human relevance. The first step was a male 
rat lifetime study in London on responses to 
continuous dietary administration of OTA 
(3), which revealed only a 20 % incidence of 
kidney cancer at a daily OTA intake similar 
to that at the high dose of the NTP study, if 
expressed as the average daily intake 
through a week (3). This expression is 
relevant to a commonly used unit in toxicity 
risk analysis, namely the tolerable weekly 
intake (TWI). The London study, and all 
subsequent ones there, used delivery nearer 
to natural contamination by including both 
the nephrotoxin and the mould that 
produced it, and voluntary dietary 
consumption enabled natural intestinal 
absorption over a longer period in a day 
than that consequent on oral gavage. 
Continuous dietary delivery also avoided the 
temporary decline in circulating OTA 
concentration in blood during the two 
weekly ‘rest days’ in applying the NTP’s 5-
day gavage regimen (4) that was also 
reflected in ochratoxin B (OTB) excretion (5). 
A further experiment in London provided 
an intake matching the NTP mid-dose (1), 
and has already been described (6). The 
present report focuses on the more striking 
pathological findings at what was, in effect, 
twice the intake of the NTP study high dose 
and which were made on animals that were 
exactly contemporary with those in the 
study by Mantle and Kulinskaya (6). The 
present report also represents the highest 
lifetime dietary OTA intake studied to date 
in F344 rats, and formed a context for 
exploring also the lifetime outcomes of the 
same dietary OTA exposure for only 10 
months. 
Materials and methods 
Production of OTA and formulation for 
dietary experiment 
Experimental design was generally the 
same as used previously (3, 6), with the 
second of which the present study was 
concurrent (6), so that the OTA source was 
identical. The UK source and experimental 
environment was the same for all animals. 
Thirty F344 male rats were used for the 
present study. Briefly, standardised OTA 
production was performed with Aspergillus 
ochraceus (7) on moist shredded wheat 
(40 g) in rotary shaken solid substrate 
fermentation in 500 ml conical flasks 
(Supplementary Figure) at 28 °C for 2 
weeks to yield batches of a product 
containing 5–6 mg OTA/g (5). Quality 
assessment of the product showed that in 
addition to OTA there was 5–10 % of OTB 
(des-chloro OTA) which is insignificantly 
bioactive as a mycotoxin; no other 
mycotoxins were produced in this 
fermentation. Each week, fermentation 
product was homogenised into powdered 
rat feed to dilute by the required factor of 
~1000 to achieve the experimental OTA 
contamination of rat diet at 5 µg/kg. Young 
rats were caged in groups of five and daily 
given 100 g feed in an aluminium foil 
container, providing 20 g/rat at 300 µg 
OTA/kg b.w. Consequently, condition of all 
animals could be inspected daily. Caged 
groups were reduced during subsequent 
growth to a maximum of three. All 
handling and procedures were carried out 
in accordance with the UK Animals 
(Scientific Procedures) Act 1986. 
Occasional blood samples (200 µl) were 
taken from a tail vein under mild general 
anaesthesia, centrifuged, and plasma 
separated for validated quantitative OTA 
analysis contracted to the Central Science 
Laboratory, York, where original quality 
assessments were also made. 
Histology 
Autopsy was performed on all animals 
found dead, euthanized when clinically 
necessary or on completion of 2 years of 
dietary OTA treatment. Kidneys and other 
tissues of potential histopathological 
interest were variously in whole or part 
either frozen in liquid nitrogen 
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Figure 1. Comparative mean body weight in control and OTA-treated groups from the beginning of 
dietary OTA exposure (10 weeks old), showing matching of treated rats and controls during the first 
10 months and significant increase to a new maximum in the sub-group that ceased OTA at that 
time. 
(subsequently archived at -70°C) or fixed in 
buffered formalin and processed 
automatically for 3 µm-sections and 
stained with haematoxylin and eosin  
(H & E) at the Breast Pathology Laboratory, 
Guy’s Hospital, London. 
Results 
Transferring young rats from standard rat 
diet to the OTA-contaminated experimental 
diet may have contributed to the initial 
diminution of growth rate (Figure 1), but 
this was only temporary. Otherwise, the 
OTA diet was always fully consumed, and 
growth of OTA diet-treated rats during the 
first year corresponded closely to that of 
controls. Thereafter, the weight gain in the 
10-month OTA group was probably a 
significant response to healthier feed, while 
rats on continuous OTA just maintained 
weight. A commentary on OTA 
pharmacokinetics in the middle of ‘lifetime’ 
exposure to the contaminated diet is 
evident in Figure 2, showing steady decline 
in plasma OTA concentration from the 
steady state of ~11 µg/ml when the 10-
month exposure to OTA ceased, 
corresponding to a plasma half-life of about 
10 days.  
Notably, OTA exposure had no adverse 
effect on longevity (Figure 3), by 
comparison with untreated controls. In the 
latter, high incidence (69%) of the 
mononuclear leukaemia that is 
characteristic in ageing F344 (Fischer) rats 
was evident, but simple reading of the 
findings in Figure 3 suggests that 
continuous OTA ingestion may have 
somewhat delayed or prevented  leukaemia 
(42%). Notably, inclusion of the 10-month 
group halves the overall leukaemia value to 
35 %. 
Although there was a latency of at least 
half-a-lifetime between cessation of the 10-
month OTA exposure and discovery of 
renal tumours causing overt morbidity, 
continuous exposure appeared to be a little 
less carcinogenic. However, it was striking 
during the experiment that 75% of the 
continuous OTA group had already 
deceased before any morbidity was 
detected in the 10-month group. Combined 
incidence of kidney cancer was 70 %; there 
is no intention to claim any particular 
significance of the 100% cancer incidence 
in the 10-month exposure group. 
No difference was perceived between the 
array of kidney tumours arising from 10 
months of OTA intake or continued 
exposure for life. Conformation of kidney 
cancer perceived as and when animals’ 
well-being necessitated termination, varied 
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Figure 2. Comparative changes in plasma OTA concentration in groups of five rats during the month 
after either continuing or ceasing 10 months of daily exposure to 300 µg OTA/kg b.w. The slope of the 
ceasing group corresponds to a plasma half-life of 10 days. 
widely in magnitude, uni- or bi-lateral, and 
the extent to which it appeared to have 
become a factor in clinical health. This was 
conditional on the propensity of Fischer rats 
to develop the particular mononuclear 
leukaemia (8). Morphology and histology are 
illustrated in Figures 4–6. Tumours 
apparently arose at a single focus in the 
region of the cortico-medullary junction. In 
some cases, tumour proliferation occurred 
by infiltration into the cortical parenchyma, 
destroying kidney morphology although 
retaining glomeruli as structural entities 
(Figure 4D); in others, the tumour retained 
a discrete junction with renal parenchyma 
(Figure 4F) and expanded to distort kidney 
morphology either within the stretched 
capsule or by rupturing it. Occasionally 
distant metastasis occurred (Figure 5D). 
The renal tumourigenicity of OTA exposure 
during only 10 months eventually became 
apparent in all rats, but its clinical 
expression after about 11 months’ latency 
was markedly delayed relative to the 
continuous OTA group (Figure 3). This may 
have been, in part, due to animals being 
unhindered by development of leukaemia 
and their consequential premature demise. 
However, sufficient genetic change had 
obviously been achieved during 10 months 
of exposure of proximal tubule epithelia to a 
relentless flow of OTA molecules during 
toxin elimination. 
Chronological timeline summaries 
(correlated with Figure 3) of gross 
pathology in rats given OTA are listed 
below. Diagnosis of leukaemia became 
obvious from marked splenomegaly. 
Microscopically, karyomegaly was evident 
in kidneys of all OTA-treated rats. 
For 10-month exposure 
 Right kidney carcinoma at cranial pole 
(9.9 g). Splenomegaly. 
 Left kidney carcinoma (49 g); right kidney 
carcinoma on contra-pelvis aspect (3 g). 
Metastatic nodules on abdominal serous 
surfaces (Figure 5). 
 Left kidney carcinoma (11.1 g). 
Metastases in lungs. 
 Left renal mass (~100 g) including 
carcinoma and hydronephrotic balloon 
containing ~30 ml fluid (Figure 6). Right 
kidney containing sub-capsular 
carcinoma (1.2 g). Splenomegaly. 
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Figure 3. Course of outcomes for longevity, incidence of leukaemia, occurrence of renal tumours and 
distant metastases in male F344 rats given dietary ochratoxin A (300 µg/kg b.w.) from 8 weeks old 
continuously or for only 10 months, displayed from week 65 and compared with controls. Yellow 
indicates leukaemia, and red shows renal cancers with metastatic extension where appropriate. 
 Cryptic carcinoma (2  3 mm) in one 
kidney. Splenomegaly. One testis 
atrophied; one hypertrophied but not 
tumorous. 
Continuous exposure 
 Splenomegaly. 
 Found dead; bilateral kidney carcinoma 
(left, 10.8 g; right 5.5 g). 
 Found dead; extensive ascites. Kidneys 
morphologically normal (karyocytomegaly 
recognised in the outer stripe of the outer 
medulla). Liver very pale, possibly 
tumourous but not studied because of 
postmortem deterioration. 
 Left kidney carcinoma at pole (2.4 g). 
Metastatic nodules on ileum surface. 
Splenomegaly. 
 Left kidney carcinoma on contra-pelvic 
aspect. Metastatic nodules on 
abdominal serosal surfaces, in lung and 
in liver. 
 Right kidney carcinoma (27 g). 
 Splenomegaly. 
 Left kidney carcinoma (8.9 g). Metastases 
in lung. 
 Splenomegaly. 
 Large abdominal sub-cutaneous sarcoma 
(6  4 cm). Left kidney carcinoma at polar 
aspect (4 g). Right kidney carcinoma at 
polar aspect (1.4 g). 
 Right kidney carcinoma at cranial pole  
(8 g). 
 Splenomegaly. 
Discussion 
In comparison with findings from the 
previous 6-fold lower dosage experiment 
with a 12 % tumour incidence (6), steady-
state concentration of OTA in blood plasma 
had risen proportionately (from 1–2 to  
~11 µg/ml), corresponding both to the 
dose–factor difference and the subsequent 
58–100% incidence of renal cancer in the 
two recent sub-groups (mean incidence, 
70%). The 10-day plasma half-life of OTA in 
F344 rats means that the blood 
compartment ultimately controls the rate of 
OTA excretion through renal parenchyma. 
On a body weight basis the rats’ weekly 
dietary OTA intake in the present study 
was 17,500-fold greater than the current 
human tolerable weekly intake (TWI) value 
of 120 ng/kg b.w. (9), emphasising the very 
high and protracted experimental OTA 
exposure necessary to achieve their 
abundant renal cancer incidence. 
Comfortable integration of the present 
tumour incidence into the log dose-
response relationship for OTA in the rats 
(2, 10) has reinforced the steepness of that 
curve for the Fischer strain and 
emphasised the nil carcinogenicity of a 
threshold exposure. However, natural 
human intake rarely approaches the 
prescribed TWI. 
Previous use of Dark Agouti young adult 
males fed with dietary OTA (5 µg/g feed, 
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Figure 4. A range of rat macro- and micro-renal tumours from chronic dietary exposure to ochratoxin 
A. A, Longitudinal section through kidney, and tumour. B, Longitudinal half of kidney and tumour, 
fixed in formalin. C, Fresh half of kidney with necrotic centre and bounded by traces of original 
kidney. D, Glomerulus surrounded by tumour infiltrated into surrounding cortex. E, Micro-tumour 
located at the cortico-medullary junction. F, Junction between micro-carcinoma and kidney 
parenchyma showing karyocytomegaly in both tissues. G, Micro-carcinoma with small necrotic centre. 
B and C, Lifetime exposure to ochratoxin A; the rest relate to 10-month exposure. 
delivering three times the high dose of the 
NTP study (1)) found no renal neoplasms 
after 3-month exposure; one animal with 
bi-lateral kidney cancer out of 20 replicates 
(16 %) after 6 months, and four uni-lateral 
kidney cancers out of 20 replicates after  
9-month exposure (11). All were found at 
the usual natural life span of this strain. 
Also, the threshold value in the NTP study 
has been lifted to ~30 µg/kg b.w. in Dark 
Agouti rats (11). That strain does not have 
a leukaemia component to confuse 
diagnostic attribution of ageing mortalities, 
so that experimental nil carcinoma and rat-
tolerable continuous exposure and weekly 
intake for life are still proportionately 
~1750-fold greater than the human TWI 
value implies. The TWI value already 
contains a 500-fold safety factor. Therefore, 
whereas rat experiments are informative 
concerning OTA’s renal carcinogenicity, 
they should not be used to support undue 
hyperbole concerning human toxic risk 
from daily dietary exposures that are 
common only in the low ng/kg b.w. range. 
Renal cancer incidence of 58% in the 
continuous OTA group here is twice that of 
a previous study (3) in which the  
300 µg/kg b.w. daily dosage was held at 
100 µg/rat after 4 months of the high-dose 
treatment. The present higher OTA 
exposure during the remaining 6 months of 
what seems a sufficient 10 months of 
carcinogenic exposure could account for 
the higher incidence of renal cancers, even 
if continuing exposure through a second 
year makes little or no difference to cancer 
outcomes. Although all animals of the 
present study together with those of the 
study by Mantle and Kulinskaya (6) were 
initially placed randomly in groups of five, 
no statistical significance is accorded in the 
present study between renal cancer 
incidence values in the OTA-treated groups 
of five (as originally designated as a group) 
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Figure 5. Continuous ochratoxin A. A and B, Hyperplastic renal tubule lesions in transverse and 
oblique sections with karyocytomegaly. C, Contrasting histology at renal tumour edge. D, Extensive 
nodules in serosal surfaces in upper abdomen, presumed metastatic from kidney carcinoma. 
and 12 rats (from three original groups) 
(Figure 3); there is just a general high 
incidence throughout. 
Cumulative OTA consumption of rats in 
the present 10-month dosing group was 
~30 mg and, in those continuing for 
lifetime, in the range ~50–65 mg. In an 
acute study (12), a single 6.25 mg gavage 
dose to three mature males (15 months old) 
caused marked temporary morbidity, but 
there was normal subsequent well-being 
and longevity and no neoplastic 
histopathological changes were found. 
Whereas NTP historical lifetime incidence 
of mononuclear leukaemia in F344 rats, 
and that in the 1989 study controls (1), 
was approximately 20%, the lower 
incidence in females in the 1989 study at 
mid- and high-OTA dose (4% and 6%, 
respectively) is intriguing. Notably, in spite 
of the OTA exposure, though insensitivity 
to carcinogenicity for males, their longer 
life still failed to match the leukaemia 
incidence of controls. However, incomplete 
data collection on that topic precluded 
statistical analysis. In males, leukaemia 
was 14% across all OTA dose rates, but 
these values could not support any firm 
conclusion about a protective effect of OTA 
exposure. In the London study, two 
decades later, there was a 70% leukaemia 
incidence in ageing male Fischer rats, but 
half this value across the 17 animals given 
OTA (300 µg/kg b.w.) for at least a year, 
and an intermediate value of 50% for the 
rats given the 50 µg/kg b.w. regimen (6).  
In an analogous study (13), 24 male rats 
ingested ~250 µg OTA/kg b.w. for 35  
weeks from 50 weeks of age (cumulative 
~24 mg OTA). Plasma OTA reached  
8 µg/ml within 4 weeks. Leukaemia 
incidence was 38%, associated with four 
cases of kidney adenoma but there was no 
cancer. It is tantalising to consider whether 
this evidence points, together with that in 
the NTP study, to a protective effect on  
leukaemia of chronic OTA ingestion, 
including at a renal tumourigenic exposure 
rate. Such protective magnitude is of an 
order much welcomed for pharmaceutical 
medications. It may also be contemplated 
why OTA exposure in the latter year (13) 
was so weakly tumourigenic, more closely 
matching the response of female rats to 
OTA (1). The hypothesis of augmented 
glomerular transport of OTA bound to a 
urinary globulin and absorbed into 
proximal tubule epithelia by male rats (14) 
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Figure 6. Ochratoxin A for 10 months only. A, Abdominal distortion by hydronephrotic renal cancer 
after 1 year of latency. B, Exposure of tumorous kidney orientated by the intact papilla and showing 
tumour in a discrete region. C, Detail of disorganised tumour histopathology. 
might apply here. The alpha2u-globulin is 
synthesised only in the male in response to 
testosterone and synthesis will decline with 
ageing, potentially reducing OTA’s 
augmented transfer into nephron epithelia. 
The long latency of rat renal 
tumourigenesis shows that OTA is not 
required for tumour enlargement and 
proliferation, but many months of exposure 
above a threshold daily intake of about  
30 µg/kg b.w. are needed in the first year 
of life for the initiation of specific changes 
in one or a few proximal tubule segments. 
Human dietary exposure to OTA, usually in 
very small amount, is reflected in blood 
(including that of the author) in trace 
amounts by sophisticated analysis (not 
available for the NTP study of the 1980s) 
and OTA-DNA adducts can be detected in 
some tissues by 32P post-labelling 
methodology. However, it is fantasy to 
employ homeopathic-like philosophy to 
ascribing a human renal carcinogenic 
property to OTA, without support of human 
exposure matching necessary experimental 
findings. There remains no experimental 
evidence that OTA can cause human 
urothelial cancer such as that associated 
with the Balkan endemic nephropathy 
(BEN); OTA-DNA adducts may be found in 
such tumours but only indicate exposure, 
and as yet do not prove tumour initiation. 
To illustrate that rat responses do not 
automatically translate to the human, and 
concerning the renal karyomegaly found in 
OTA-treated rats, it is difficult to ignore 
contrasting findings in another mycotoxin-
induced nephrotoxicity. This focuses on 
proximal tubules in the outer stripe of the 
outer medulla (OSOM) in response to a 
Penicillium polonicum–moulded wheat 
extract, causing striking karyocytomegalic 
changes in the rat but no response in a 
vervet monkey (15). Karyomegaly is 
widespread within OTA renal tumours (1). 
These nuclei have a complex DNA ploidy 
distribution within a range in which all 
without a regular multiplicity of the 
genome are aneuploid and are therefore 
potentially unstable (16). During 
continuous exposure to dietary OTA, 
karyomegaly frequency increases over 
many months within parenchyma of the 
OSOM (3, 17), but this does not necessarily 
indicate that carcinoma has yet been 
initiated. In P. polonicum nephropathy, 
karyomegaly is accompanied by apoptosis, 
as revealed by ApopTag Direct analysis 
(18). However, OTA treatment did not 
cause significant apoptosis, suggesting that 
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OTA is unlikely to be involved in the 
progressive bi-lateral renal atrophy of BEN. 
Further, recent immunohistochemical 
study of rat OTA tumours (19) shows that 
they resemble the unique spontaneous 
tumours of the Eker rat and may not 
therefore be immediately predictive of what 
might happen in human kidney and are 
even less likely to mimic the carcinomas in 
some BEN patients even if some of these 
neoplasms occur in urothelium within the 
renal pelvis. Hence, the recent opinion (20) 
that OTA should officially be reclassified as 
carcinogenic to humans seems ill-judged 
on the basis of such sparse evidence, 
ignoring rigorous principles of disease 
epidemiology (21, 22). 
While focusing here on kidney cancer, the 
precise origin of carcinoma(s) in other 
organs/sites arises because the literature 
since the NTP report (1) has consistently 
assigned these to being metastatic from the 
kidney tumour. While the assumption may 
be correct, it has not been subject to 
immunohistochemical verification. The 
matter is currently a work in progress, 
based on the present experiments and of 
those lodged in the NTP Archives. Further, 
since full DNA exome sequence data have 
now been obtained from archived frozen 
cancers of the present rat study, 
interpretation is also currently a work in 
progress. It is important to seek matching 
genome change in rats and humans to 
address current poorly informed 
speculation. 
Acknowledgements 
I gratefully acknowledge skilled animal 
husbandry and phlebotomy by staff of the 
Imperial College Central Biomedical 
Services, histological preparation at the 
Breast Pathology Laboratory, Guy’s 
Hospital, London, and funding from the 
European Union (contract no. QLK1-CT-
2001–011614). 
Conflict of interest 
The author declares no potential conflicts 
of interest with respect to research, 
authorship and/or publication of this 
article. 
None. 
References 
1. Boorman GA. Toxicology and 
carcinogenesis studies of ochratoxin A 
(CAS No. 303-47-9) in F344/N rats (gavage 
studies). National Toxicology Program. 
Technical Report 358. 
2. Waddell WJ. Critique of dose response in 
carcinogenesis. Hum Exp Toxicol. 
2006;25:413–66.  
3. Mantle P, Kulinskaya E, Nestler S. Renal 
tumourigenesis in male rats in response to 
chronic dietary ochratoxin A. Fd add 
Contam. 2005;22 Suppl 1:58–64. 
4. Mally A, Volkel W, Amberg A, Kurz M, 
Wanek P, Eder E, et al. Functional, 
biochemical, and pathological effects of 
repeated oral administration of ochratoxin A 
to rats. Chem Res Toxicol. 2005;18:1242–52. 
5. Mally A, Keim-Heusler H, Amberg A, 
Kurz M, Zepnik H, Mantle P, et al. 
Biotransformation and nephrotoxicity of 
ochratoxin B in rats. Toxicol Appl 
Pharmacol. 2004;206:43–53. 
6. Mantle P, Kulinskaya E. Lifetime, low-
dose ochratoxin A dietary study on renal 
carcinogenesis in Male Fischer rats. Fd 
Add Contam Part A. 2010;27:1566–73. 
http://dx.doi.org/10.1080/19440049.201
0.502302 
7. Harris JP, Mantle PG. Biosynthesis of 
ochratoxin A by Aspergillus ochraceus. 
Phytochemistry. 2001;58:709–16. 
8. Molony WC, Boschetti AE, King VP. 
Spontaneous leukemia in Fischer rats. 
Cancer Res. 1970;30:41–3. 
9. EFSA. Opinion of the scientific panel on 
contaminants in the food chain on a 
request from the Commission related to 
ochratoxin A in food. EFSA J. 2006;365: 
1–56. 
10. Mantle PG. Interpretation of the 
pharmacokinetics of ochratoxin A in blood 
plasma of rats, during and after acute or 
chronic ingestion. Fd Chem Toxicol. 
2008;46:1808–16. 
http://dx.doi.org/10.1016/j.fct.2008.01.0
20 
 
Mantle Ochratoxin and rat kidney cancer 
 
Journal of Kidney Cancer and VHL 2016; 3(3):1-10.              http://jkcvhl.com 10 
 
11. Mantle PG. Minimum tolerable 
exposure period and maximum threshold 
dietary intake of ochratoxin A for causing 
renal cancer in male Dark Agouti rats. Fd 
Chem Toxicol. 2009;47:2419–24. 
http://dx.doi.org/10.1016/j.fct.2009.05.0
43 
12. Mantle PG, Nicholls AW, Shockcor JP. 
1H NMR spectroscopy-based metabolomic 
assessment of uremic toxicity, with 
toxicological outcomes, in male rats 
following an acute, mid-life insult from 
ochratoxin A. Toxins 2011;3:504–19. 
http://dx.doi.org/10.3390/toxins3060504 
13. Mantle PG, Nolan CC. Pathological 
outcomes in kidney and brain in male 
Fischer rats given dietary ochratoxin A, 
commencing at one year of age. Toxins. 
2010;2:1100–10. 
http://dx.doi.org/10.3390/toxins2051100 
14. Mantle PG, Nagy JM. Binding of 
ochratoxin A to a urinary globulin: a new 
concept to account for gender difference in 
rat nephrocarcinogenic responses. Int J 
Mol Sci. 2008;9:719–35. 
15. Mantle PG, McHugh KM, Fincham JE. 
Contrasting nephropathic responses to oral 
administration of extract of cultured 
Penicillium polonicum in rat and primate. 
Toxins. 2010;2:2083–97. 
http://dx.doi.org/10.3390/toxins2082083. 
16. Brown AL, Odell EW, Mantle PG. DNA 
ploidy distribution in renal tumours 
induced in male rats by dietary ochratoxin 
A. Exp Toxicol Pathol. 2007;59:85–95. 
17. Nestler S. Experimental renal 
ochratoxicosis; a molecular and 
pathological study in the rat. Ph.D. thesis, 
University of London, 2007. 
18. Mantle PG, Miljkovic A, Udupa V, 
Dobrota M. Does apoptosis cause renal 
atrophy in Balkan endemic nephropathy? 
Lancet. 1998;352:1118–9. 
19. Gazinska P, Herman D, Gillett C, 
Pinder S, Mantle P. Comparative 
immunohistochemical analysis of 
ochratoxin A tumourigenesis in rats and 
urinary tract carcinoma in humans; 
mechanistic significance of p-S6 ribosomal 
protein expression. Toxins. 2012;4:643–
62. 
http://dx.doi.org/10.3390/toxins4090643 
20. Malir F, Ostry V, Pfohl-Leszkowicz A, 
Malir J, Toman J. Ochratoxin A: 50 years 
of research. Toxins. 2016;8:E191. 
http://dx.doi.org/10.3390/toxins8070191 
21. Koch R. Untersuchungen über 
Bakterien: V. Die Ätiologie der 
MilzbrandKrankheit, begründet auf die 
Entwicklungsgeschichte des Bacillus 
anthracis. Cohns Beitrage zur Biologie der 
Pflanzen. 1876;2:277–310. 
22. Hill AB. The environment and disease: 
association or causation? 1965. J R Soc 
Med. 2015;108:32–7. 
 
